Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
ProfoundBio is headquartered in Seattle, Washington, with an R&D center of innovation in Suzhou, China, and has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological malignancies. The development will give Genmab worldwide rights to three clinical candidates, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms. The acquisition is expected to enhance Genmab's mid- to late-stage clinical pipeline, expand Genmab's pipeline, and enhance its cancer treatment capabilities, with Rina-S as a potential best-in-class ADC targeting ovarian cancer and solid tumors. Rina-S, which is in a Phase 2 study for ovarian cancer, is also being explored as a therapy for other solid tumors. With the addition, Genmab's operating expenses are projected to rise to the upper end of their guidance range of DKK 12.4–13.4 billion, primarily due to the additional R&D investment in ProfoundBio'
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale [BNN Bloomberg (Canada)]BNN Bloomberg
- Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion [Seeking Alpha]Seeking Alpha
- Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Denmark's Genmab to acquire ProfoundBio for $1.8 billion [Reuters]Reuters